OncoTEX Receives Notice of Allowance for Patent in Korea Regarding Ovarian Cancer-Fighting Drug OxaliTEX Notice of allowance of OxaliTEX patent in Korea adds further global protection OxaliTEX has already been granted patent protection in the U.S., Australia, Singapore, Mexico and Israel AUSTIN,...

OncoTEX Issued New U.S. Patent for Ovarian Cancer-Fighting Drug OxaliTEX AUSTIN, Texas, March 14, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing first-in-class cancer pharmaceuticals that are tumor localizing, exhibit low side effects, target both...

Chemical Society Reviews Journal Explores How OncoTEX’s Gold-Based Compounds Can Activate the Immune System to Fight Cancer AUSTIN, Texas, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OncoTEX Inc., an oncology company developing first in class cancer therapeutics that are well-tolerated, MRI-detectable, and target drug-sensitive...